Biocryst Pharmaceuticals Stock News

RESEARCH TRIANGLE PARK, N.C., Feb. 09, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its fourth quarter and full year 2021 financial results Wednesday, February 23, 2022.

Royalty Pharma and OMERS Capital Markets (OMERS) recently committed $350 million in non-dilutive funding for BioCryst. BioCryst generated $120 million from their flagship product Orladeyo in FY2021 an

BioCryst Pharmaceuticals (BCRX) board granted 31 newly-hired employees stock options to purchase 213.5K shares and restricted stock units covering 24.7K shares.The options have an…

RESEARCH TRIANGLE PARK, N.C., Feb. 03, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors gran

RESEARCH TRIANGLE PARK, N.C., Feb. 01, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present three abstracts featuring new data on oral

RESEARCH TRIANGLE PARK, N.C., Feb. 01, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present three abstracts featuring new data on oral,

Looking for a healthcare stock that will pay you to own it? Here are three suggestions.

Biocryst Pharmaceuticals Inc. (BCRX) shares closed this week 30.0% higher than it did at the end of last week. The stock is currently up 16.6% year-to-date, up 98.2% over the past 12 months, and up 158.4% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 fell 0.7%. Trading Activity Shares traded as high as $17.35 and as low as $12.25 this week.Shares closed 16.2% below its 52-week high and 84.9% above its 52-week low.Trading volume this week was 29.7% lower than the 10-day average and 28.3% higher than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.9. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought.The stock closed at 2.7% lower than its 5-day moving average, 10.5% higher than its 20-day moving average, and 13.0% higher than its 90-day moving average. Market Comparative Performance The company's share price beats the S&P 500 Index this week, beats it on a 1-year basis, and beats it on a 5-year basis The company's share price beats the Dow Jones Industrial Average this week, beats it on a 1-year basis, and beats it on a 5-year basis The company share price beats the performance of its peers in the Health Care industry sector this week, beats it on a 1-year basis, and beats it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by -235.2% The company's stock price performance over the past 12 months beats the peer average by -2623.8% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Investors loved the drugmaker's update earlier this week.

Investors loved the drugmaker''s update earlier this week.

Investors loved the drugmaker's update earlier this week.

Biocryst Pharmaceuticals Inc. (BCRX) shares closed today 11.2% higher than it did at the end of yesterday. The stock is currently up 6.7% year-to-date, up 91.0% over the past 12 months, and up 138.8% over the past five years. Today, the Dow Jones Industrial Average rose 0.5%, and the S&P 500 rose 0.9%. Trading Activity Shares traded as high as $14.82 and as low as $11.55 this week.Shares closed 11.1% below its 52-week high and 117.6% above its 52-week low.Trading volume this week was 211.5% higher than the 10-day average and 364.6% higher than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.8. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price beats the S&P 500 Index today, beats it on a 1-year basis, and beats it on a 5-year basis The company's share price beats the Dow Jones Industrial Average today, beats it on a 1-year basis, and beats it on a 5-year basis The company share price beats the performance of its peers in the Health Care industry sector today, beats it on a 1-year basis, and beats it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by -197.4% The company's stock price performance over the past 12 months beats the peer average by 1971.8% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

The week began in the best possible way for BioCryst (BCRX) investors. Shares saw out Mondays session with 28% of gains attached to the ticker, as the market appla